SH3D19 Inhibitors
SH3D19 inhibitors represent a specific class of chemical compounds designed to interact with and inhibit the function of the SH3D19 protein, which belongs to the SH3 (Src Homology 3) domain-containing family. The SH3 domain is a small protein domain typically involved in protein-protein interactions, characterized by its ability to recognize and bind to proline-rich motifs. SH3D19, in particular, is distinguished by its structural features that enable its participation in signal transduction pathways, molecular scaffolding, and various cellular processes that depend on intricate protein networks. The inhibition of SH3D19 involves disrupting these protein-protein interactions, which may play a role in modulating intracellular signaling cascades, influencing the overall dynamics of cellular communication, and contributing to the regulation of molecular processes such as endocytosis, cytoskeletal arrangement, and vesicular transport.
The development of SH3D19 inhibitors relies on an understanding of the molecular recognition patterns that govern SH3 domain interactions. These inhibitors typically function by occupying the binding pockets of the SH3D19 domain, preventing it from associating with its proline-rich interaction partners. The design of such inhibitors requires a precise analysis of the three-dimensional structure of SH3D19, with particular attention paid to its hydrophobic pockets and charge distributions that define its binding affinities. Advances in computational modeling and structure-based design have facilitated the optimization of inhibitor binding characteristics, enhancing their specificity and stability when interacting with SH3D19. By targeting SH3D19, these inhibitors provide a valuable tool for dissecting the protein's role in cellular networks and for exploring the broader biological implications of SH3-mediated interactions.
SEE ALSO...
Items 1 to 10 of 11 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Erlotinib, Free Base | 183321-74-6 | sc-396113 sc-396113A sc-396113B sc-396113C sc-396113D | 500 mg 1 g 5 g 10 g 100 g | $85.00 $132.00 $287.00 $495.00 $3752.00 | 42 | |
Erlotinib is an epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor. SH3D19, being a protein with an SH3 domain, may be indirectly influenced by changes in EGFR signaling because EGFR can initiate downstream signaling cascades that can modulate the binding and activity of SH3 domain-containing proteins. The inhibition of EGFR by Erlotinib could, therefore, impede the signaling events that SH3D19 is involved in. | ||||||
Dasatinib | 302962-49-8 | sc-358114 sc-358114A | 25 mg 1 g | $47.00 $145.00 | 51 | |
Dasatinib is a multi-targeted kinase inhibitor, known to affect the Src family kinases. Since SH3 domains are involved in the interactions with proline-rich motifs on kinases like Src, Dasatinib may disrupt these interactions, leading to a decreased functional activity of SH3D19 by preventing its association with its targets. | ||||||
PP 2 | 172889-27-9 | sc-202769 sc-202769A | 1 mg 5 mg | $92.00 $223.00 | 30 | |
PP2 is a selective inhibitor of Src family tyrosine kinases. It would inhibit the activity of proteins that require Src for signaling, potentially including SH3D19 if it interacts with Src family kinases. This could lead to a reduction in SH3D19-mediated signaling events. | ||||||
PIK-75, hydrochloride | 372196-77-5 | sc-296089 sc-296089A | 1 mg 5 mg | $28.00 $122.00 | ||
PIK-75 is a PI3K inhibitor, which could also affect the activity of SH3D19 indirectly, considering the broad role of PI3K signaling in regulating various SH3 domain-containing proteins and their associated pathways. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $121.00 $392.00 | 148 | |
LY294002 is another PI3K inhibitor, functioning similarly to PIK-75, possibly leading to reduced activity of SH3D19 through the broad inhibition of the PI3K/AKT pathway. | ||||||
PD 98059 | 167869-21-8 | sc-3532 sc-3532A | 1 mg 5 mg | $39.00 $90.00 | 212 | |
PD98059 is also a MEK inhibitor and could have a similar effect on SH3D19 as U0126 by dampening the ERK pathway and potentially affecting SH3D19's role within this pathway. | ||||||
SP600125 | 129-56-6 | sc-200635 sc-200635A | 10 mg 50 mg | $40.00 $150.00 | 257 | |
SP600125 is an inhibitor of JNK, which is part of the MAPK pathway. SH3D19 might be affected by the inhibition of JNK if it is involved in JNK-mediated signaling processes. | ||||||
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $88.00 $342.00 | 284 | |
SB203580 is a p38 MAPK inhibitor, which could inhibit the p38 pathway and thus indirectly decrease the function of SH3D19 if it is involved in p38-mediated signaling. | ||||||
Wortmannin | 19545-26-7 | sc-3505 sc-3505A sc-3505B | 1 mg 5 mg 20 mg | $66.00 $219.00 $417.00 | 97 | |
Wortmannin is a potent and irreversible inhibitor of PI3K. It could lead to reduced SH3D19 activity by broadly inhibiting PI3K/AKT signaling, which might be necessary for SH3D19's function. | ||||||
Gefitinib | 184475-35-2 | sc-202166 sc-202166A sc-202166B sc-202166C | 100 mg 250 mg 1 g 5 g | $62.00 $112.00 $214.00 $342.00 | 74 | |
Gefitinib is another EGFR tyrosine kinase inhibitor, similar to Erlotinib. It would inhibit EGFR signaling and potentially reduce SH3D19 activity if SH3D19 is part of the EGFR signaling cascade. | ||||||